Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KaloBios Can Get Priority Review Voucher With 505(b)(2) Chagas Application

Executive Summary

US FDA’s recent guidance on the program notes that even tropical disease products approved under 505(b)(2) are eligible for a priority review voucher.

You may also be interested in...



Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up

The latest drug development news and US FDA highlights from our Performance Tracker.

KaloBios Rises From Bankruptcy Ashes With PRV Still Firmly In Its Sights

KaloBios Pharmaceuticals Inc.'s CEO Dr Cameron Durrant has ticked off two major tasks from his to-do list in his bid to turn the company around after it was caught in the firestorm of Martin Shkreli's fall from grace. He talks to Scrip about the company's strategy, his vision of a responsible pricing model, and the possibility that KaloBios' actions might help rehabilitate pharma's image.

KaloBios Pledges To Do The Right Thing On Drug Pricing

In an interview, CEO Cameron Durrant said the time was right for KaloBios to outline its pricing strategy as the company looks to emerge from the Martin Shkreli scandal and bankruptcy.

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel